Abstract
Pharmaceutical companies are now looking more to increasing numbers of Eastern European countries to conduct clinical studies. Various advantages accrue from these countries, notably cheaper cost and naive patient populations. However, there is the danger of false economy with cheaper meaning poorer quality. Published results appear contradictory, with some confirming more major Good Clinical Practices violations in Eastern Europe than in Western Europe, while others suggest the reverse. Experience when conducting audits carried out in Eastern Europe has revealed that problems do exist. Many of the problems lie with the failure of the sponsor companies to provide adequate training for both monitors and investigators. Commitment by investigators in Eastern Europe is high and a small amount of time and finance invested in training could be rapidly repaid through high-quality studies.
Similar content being viewed by others
References
Idänpään-Heikkilä JE. Globalising guiding principles for clinical trials: Good Clinical Practice beyond the European Union, the United States and Japan. Good Clin Practice J. 1999;6(6): 13–15.
CIOMS International ethical guidelines for biomedical research involving human subjects. Geneva, Switzerland: Council of International Organizations of Medical Sciences; 1993.
Paál DI. Recent changes in clinical trial authorization in Eastern Europe. Drug Inf J. 1997;31:151–155.
Brunier PB, Nahler GR. GCP deficiencies in clinical trials in Western and Eastern Europe. Appl Clin Trials. 1998:46–51.
Natorff BL. Experiences of a CRO operating in Central and Eastern Europe. European Pharma Contrac. November 1999:118–126.
Natorff BL. Clinical trials in Central/Eastern Europe: Industry viewpoint. Drug Inf J. 1998;32:129–133.
Hughes G. Contract clinical research in Central and Eastern Europe. Appl Clin Trials. 1994;3:52–59.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Neal, H. The Contract Research Organization Perspective: Audits in Central and Eastern European Countries. Ther Innov Regul Sci 35, 475–480 (2001). https://doi.org/10.1177/009286150103500216
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150103500216